drugset
Drugs / bictegravir/emtricitabine/tenofovir alafenamide
last change Apr 2025 re-read 3 minutes ago

bictegravir/emtricitabine/tenofovir alafenamide

also known as Single-tablet regimen BIC/FTC/TAF or Biktarvy
Developed for
HIV infectious disease
Investigated by
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · National Institute of Allergy and Infectious Diseases (NIAID)

Trials 1

today NCT02859558 · Ph 2
20172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT02859558 Jan 2017 → Dec 2020 HIV infectious disease Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections Completed Missed primary

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as bictegravir/emtricitabine/tenofovir alafenamide ClinicalTrials.gov intervention name — accepted as the source's own label NCT02859558 ↗
Known as Single-tablet regimen BIC/FTC/TAF or Biktarvy “Single-tablet regimen BIC/FTC/TAF or Biktarvy” NCT02859558 ↗
Route Oral “by mouth daily with or without food” NCT02859558 ↗